JANX (Janux Therapeutics) FFO


JANX Janux Therapeutics Inc JANX
47 GF Score
Price $14.94
GF Value $39.28
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Janux Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

JANX
47GF Score
Janux Therapeutics Inc JANX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Janux Therapeutics (JANX) Overvalued in 2026?

Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued. The current stock price of $14.94 is trading 62% below its estimated GF Value™ of $39.28. GuruFocus considers Janux Therapeutics to be Possible Value Trap.

Key valuation signals for JANX:

  • FFO:
  • GF Value™: $39.28 vs. price of $14.94 (62% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Janux Therapeutics Business Description

Address 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
47GF Score

Get the complete analysis for JANX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.94
Price
$39.28
GF Value